Dapagliflozin

Dapagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitors, a family of oral drugs also known as gliflozins. It was developed by Bristol-Myers Squibb together with AstraZeneca and was among the first of its class to reach the market, receiving European authorization in 2012 and approval in the United States in 2014. It is best known under the brand names Farxiga and Forxiga.

The drug was introduced as a blood-glucose-lowering treatment for type 2 diabetes, but its uses have broadened considerably as large clinical trials revealed effects on the heart and kidneys. It is now prescribed not only for diabetes but also for chronic heart failure and chronic kidney disease, including in people who do not have diabetes ^[1][2].

In heart failure, the DAPA-HF trial found that dapagliflozin lowered the risk of worsening heart failure or death from cardiovascular causes in patients with heart failure and reduced ejection fraction ^[1]. Results like these helped establish SGLT2 inhibitors as a core part of modern heart failure therapy.

In kidney disease, the DAPA-CKD trial showed that the drug reduced the combined risk of a major decline in kidney function, kidney failure, and death from renal or cardiovascular causes among people with chronic kidney disease, with the benefit broadly similar whether or not the patient had type 2 diabetes ^[2][3]. Modeling based on the trial data suggests that long-term treatment could delay progression to kidney failure by several years ^[4].

Common side effects reflect the drug's mechanism and include genital yeast infections, urinary tract infections, and dehydration with low blood pressure; there is also a small risk of diabetic ketoacidosis and, rarely, a serious infection of the genital and perineal region. Dapagliflozin is a prescription-only medicine, is listed on the World Health Organization's Model List of Essential Medicines, and is supplied as oral tablets taken once a day, with generic versions becoming available.

Dapagliflozin is prescription only and generally well tolerated, but it has specific risks tied to how it works. Spilling sugar in the urine raises the chance of genital yeast infections and urinary tract infections, and rarely a serious perineal infection called Fournier's gangrene. It can cause dehydration and low blood pressure, especially in older adults or those on diuretics. A distinctive risk is euglycemic diabetic ketoacidosis, where ketones climb even when blood sugar looks normal, so it is paused during serious illness, fasting, or surgery. It is not used for type 1 diabetes and is less potent at lowering sugar when kidney function is very low, though it stays protective within approved ranges.

Dapagliflozin's pharmacokinetic interactions are mild. It is cleared mainly by glucuronidation via UGT1A9 rather than by the cytochromes, and dedicated studies found that rifampin lowered exposure by about 22% while the strong UGT1A9 inhibitor mefenamic acid raised it by about 51%, neither with a meaningful change in urinary glucose excretion. The usual CYP3A4 questions do not apply here.

The pharmacodynamic interactions do matter. Dapagliflozin rarely causes hypoglycaemia on its own, but paired with insulin or a sulfonylurea the combined glucose lowering can drop blood sugar sharply. Because the drug works by forcing glucose and water into the urine, adding a loop or thiazide diuretic compounds volume depletion, and the result can be orthostatic hypotension or acute kidney injury, particularly in older patients. That same osmotic diuresis can lower serum lithium concentrations.

One practical consequence is diagnostic rather than clinical: dapagliflozin makes urine glucose testing and the 1,5-anhydroglucitol assay useless as measures of glycaemic control.

Checking a whole stack? Run it through interactions + stacks.

Dapagliflozin emerged from a research collaboration between Bristol-Myers Squibb and AstraZeneca, and was first described in the medical-chemistry literature in 2008 as a potent, orally stable C-aryl glucoside inhibitor of the sodium-glucose cotransporter 2. It was designed to overcome the metabolic instability of earlier phlorizin-derived compounds, and became one of the first agents of the gliflozin class to reach patients.

The drug was approved in the European Union in 2012 and, after an initial regulatory delay, in the United States in 2014 under the brand names Forxiga and Farxiga for type 2 diabetes. Subsequent large outcome trials extended its reach far beyond glucose control, leading to approvals for chronic heart failure and chronic kidney disease, including in people without diabetes. Its trajectory helped establish SGLT2 inhibition as one of the most consequential therapeutic advances in cardiometabolic medicine of the past two decades.

Dapagliflozin enjoys a strong and steadily rising reputation, having evolved from a novel glucose-lowering agent into a cornerstone of modern heart-failure and kidney-disease care. Cardiologists and nephrologists frequently praise the consistency of its benefits across large randomized trials, which showed reductions in hospitalizations and disease progression even in patients without diabetes. It is generally well tolerated and taken conveniently as a single daily tablet, adding to its appeal. Clinicians remain attentive to a modestly increased risk of genital infections and the rare occurrence of euglycemic ketoacidosis, and they counsel patients accordingly. On balance it is widely viewed as a genuinely practice-changing medicine whose value reaches well beyond its original role in diabetes.